Trial reportAdvances in therapy2020
New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study.
Trial report in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03833908 (Evaluation of the Performance of MAF-1217 on Surgery Induced DED When Administered Pre-operatively in Patients Undergoing Cataract Surgery), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Performance of MAF-1217 on Surgery Induced DED When Administered Pre-operatively in Patients Undergoing Cataract Surgery
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Risk of dry eye in headache patients: a systematic review and meta-analysis.Annals of medicine · 2022Pooled it
- Hypochlorous acid hygiene solution in patients affected by blepharitis: a prospective randomised study.BMJ open ophthalmology · 2023Trial
- Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Trial
- Comparative Efficacy of Topical Eye-Drop Regimens for Dry Eye After Cataract Surgery: A Systematic Review and Network Meta-analysis.Ophthalmology and therapy · 2026Review
- Differential Characteristics, Mechanisms, and Clinical Strategies for Perioperative Dry Eye in Presenile Cataract and Age-Related Cataract.Healthcare (Basel, Switzerland) · 2026Review
- Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study.Ophthalmology and therapy · 2026Article
- Impact of Lid Wipes and Tear Substitutes on Symptoms and Signs of Ocular Surface Disease After Cataract Surgery-A Real-Life Study.Journal of clinical medicine · 2025Article
- Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery: A Prospective Double-Masked Randomized Controlled Clinical Trial.Ophthalmology and therapy · 2025Article
- Comparison of Postoperative Outcomes in 71 Patients Undergoing Cataract Surgery at a Single Center with and Without Preoperative Keratostill Moisturizing Eye Drops.Journal of clinical medicine · 2025Article
- The Potential Role of Vitamin D in the Pterygium Pathophysiology-A Possible New Therapeutic Perspective and Narrative Review.Journal of clinical medicine · 2025Review
- Evaluation of Two Artificial Tears Containing Hyaluronic Acid for Post Cataract Surgery Dry Eye Disease: A Randomized Controlled Trial.Ophthalmology and therapy · 2024Article
- Evaluation of cyclosporine 0.05% and artificial tears for the management of dry eye disease following cataract surgery: a randomized controlled trial.Annals of medicine and surgery (2012) · 2024Article
- Preventing and Managing Iatrogenic Dry Eye Disease during the Entire Surgical Pathway: A Study Focusing on Patients Undergoing Cataract Surgery.Journal of clinical medicine · 2024Article
- Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments.Ophthalmology and therapy · 2024Article
- Natural Immunomodulators Treat the Cytokine Storm in SARS-CoV-2.Advanced pharmaceutical bulletin · 2023Review
- Prevalence and Characteristics of Dry Eye Disease After Cataract Surgery: A Systematic Review and Meta-Analysis.Ophthalmology and therapy · 2022Review
- Article
- Incremental Concentrations of Tacrolimus Eye Drops as a Strategy for the Management of Severe Vernal Keratoconjunctivitis.Frontiers in pharmacology · 2022Article
- Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study.Journal of clinical medicine · 2021Article
- A Review of Topical and Systemic Vitamin Supplementation in Ocular Surface Diseases.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the effects of a new lubricating, antioxidant solution (VisuEvo
methodsPatients requiring cataract surgery with either healthy ocular surface or mild DED (tear break-up time, TBUT > 7, Schirmer I test > 15 mm/5 min) were enrolled in this multicenter, open-label, randomized, prospective study. Scheduled visits were 2 weeks before surgery (screening), day of surgery (V0), week 1 (V1), and 2 (V2) after surgery. VisuEvo
resultsA total of 45 patients were included (group A, 23; group B, 22; age 74 ± 8 years). At the screening, TBUT was similar between the groups (group A, 8.5 ± 1.8 s; group B, 7.8 ± 0.7, p = 0.11). At the scheduled visits, TBUT increase vs screening visit was significantly higher in group A: +1.2 s at V0, +1.4 s at V1, and +1.9 s at V2 (p < 0.01). Also, OSDI was significantly lower in group A at V0, V1, and V2 (p < 0.027). After surgery, corneal staining was absent in 65-78% of group A compared with 54-59% in group B. The two groups did not show any significant differences of osmometry and the Schirmer I test.
conclusionsThe ocular surface was more protected and quickly restored from surgery when VisuEvo
trial registrationClinicalTrials.gov identifier, NCT03833908.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.